DexCom, Inc. (NASDAQ:DXCM – Get Rating) SVP Matthew Vincent Dolan sold 2,303 shares of the firm’s stock in a transaction that occurred on Thursday, March 16th. The shares were sold at an average price of $115.00, for a total value of $264,845.00. Following the completion of the transaction, the senior vice president now owns 33,569 shares in the company, valued at approximately $3,860,435. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Matthew Vincent Dolan also recently made the following trade(s):
- On Monday, March 13th, Matthew Vincent Dolan sold 6,229 shares of DexCom stock. The shares were sold at an average price of $106.27, for a total value of $661,955.83.
- On Monday, March 6th, Matthew Vincent Dolan sold 226 shares of DexCom stock. The shares were sold at an average price of $114.40, for a total value of $25,854.40.
DexCom Stock Performance
NASDAQ:DXCM opened at $113.93 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.99 and a quick ratio of 1.83. The business has a fifty day simple moving average of $111.05 and a two-hundred day simple moving average of $106.50. DexCom, Inc. has a 1 year low of $66.89 and a 1 year high of $134.76. The company has a market capitalization of $44.02 billion, a P/E ratio of 140.22, a P/E/G ratio of 2.76 and a beta of 1.10.
Analysts Set New Price Targets
A number of research firms have recently weighed in on DXCM. Wolfe Research began coverage on DexCom in a report on Thursday, January 26th. They issued an “outperform” rating and a $121.00 target price on the stock. Stifel Nicolaus raised their target price on DexCom from $120.00 to $130.00 in a report on Tuesday, December 20th. Citigroup lifted their price target on DexCom from $117.00 to $146.00 and gave the stock a “buy” rating in a report on Monday, December 12th. Morgan Stanley lifted their price target on DexCom from $117.00 to $131.00 and gave the stock an “equal weight” rating in a report on Friday, January 6th. Finally, Barclays lifted their price target on DexCom from $103.00 to $110.00 and gave the stock an “equal weight” rating in a report on Monday, February 13th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $123.00.
Institutional Trading of DexCom
A number of large investors have recently bought and sold shares of the company. KB Financial Partners LLC purchased a new position in shares of DexCom in the first quarter valued at $72,000. James Investment Research Inc. purchased a new position in shares of DexCom in the fourth quarter valued at $27,000. Close Asset Management Ltd grew its position in shares of DexCom by 200.0% in the fourth quarter. Close Asset Management Ltd now owns 264 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 176 shares in the last quarter. CoreCap Advisors LLC purchased a new position in shares of DexCom in the fourth quarter valued at $35,000. Finally, Sound Income Strategies LLC grew its position in shares of DexCom by 300.0% in the third quarter. Sound Income Strategies LLC now owns 320 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 240 shares in the last quarter. 94.01% of the stock is owned by hedge funds and other institutional investors.
DexCom Company Profile
DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.
- Get a free copy of the StockNews.com research report on DexCom (DXCM)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.